KR100320037B1 - Water-stable-form kojic acid derivatives and preparation method thereof - Google Patents
Water-stable-form kojic acid derivatives and preparation method thereof Download PDFInfo
- Publication number
- KR100320037B1 KR100320037B1 KR1019990034754A KR19990034754A KR100320037B1 KR 100320037 B1 KR100320037 B1 KR 100320037B1 KR 1019990034754 A KR1019990034754 A KR 1019990034754A KR 19990034754 A KR19990034754 A KR 19990034754A KR 100320037 B1 KR100320037 B1 KR 100320037B1
- Authority
- KR
- South Korea
- Prior art keywords
- kojic acid
- organic solvent
- water
- oxide
- stable
- Prior art date
Links
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical class OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title description 8
- 229960004705 kojic acid Drugs 0.000 claims abstract description 39
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 claims abstract description 39
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims abstract description 28
- 238000006243 chemical reaction Methods 0.000 claims abstract description 13
- KTJQXXIVWRXBCC-UHFFFAOYSA-N 2-chloro-1,3,2$l^{5}-oxazaphosphinane 2-oxide Chemical compound ClP1(=O)NCCCO1 KTJQXXIVWRXBCC-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000003960 organic solvent Substances 0.000 claims abstract description 12
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 9
- 150000007530 organic bases Chemical class 0.000 claims abstract description 7
- 239000003495 polar organic solvent Substances 0.000 claims abstract description 7
- -1 alkali metal salts Chemical class 0.000 claims description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000002585 base Substances 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- 239000008213 purified water Substances 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- JYCULSYEFRCGNR-UHFFFAOYSA-N O=P1OC=CC=N1 Chemical compound O=P1OC=CC=N1 JYCULSYEFRCGNR-UHFFFAOYSA-N 0.000 claims description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 abstract description 5
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 5
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 21
- 239000002253 acid Substances 0.000 description 11
- 239000007787 solid Substances 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000006227 byproduct Substances 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 238000004040 coloring Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 230000008099 melanin synthesis Effects 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- BKMMTJMQCTUHRP-UHFFFAOYSA-N 2-aminopropan-1-ol Chemical compound CC(N)CO BKMMTJMQCTUHRP-UHFFFAOYSA-N 0.000 description 2
- KUQZVISZELWDNZ-UHFFFAOYSA-N 3-aminopropyl dihydrogen phosphate Chemical compound NCCCOP(O)(O)=O KUQZVISZELWDNZ-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- QMOLOYHRWXFQRZ-UHFFFAOYSA-N phosphoric acid;propan-1-amine Chemical compound CCCN.OP(O)(O)=O QMOLOYHRWXFQRZ-UHFFFAOYSA-N 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 1
- NMNMPVXRUVLHHV-UHFFFAOYSA-N OCc1cc(=O)c(OC2=NP(=O)OC=C2)co1 Chemical compound OCc1cc(=O)c(OC2=NP(=O)OC=C2)co1 NMNMPVXRUVLHHV-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- ZYBWTEQKHIADDQ-UHFFFAOYSA-N ethanol;methanol Chemical compound OC.CCO ZYBWTEQKHIADDQ-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000012607 strong cation exchange resin Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 하기 구조식(I)로 표시되는 수안정형 코지산 유도체 및 그의 제조방법에 관한 것으로, 3-아미노-1-프로판올과 옥시염화인을 1 : 1~1.3의 당량비로 유기염기 존재하에 유기용매하에서 반응시켜서 생성된 2-클로로테트라히드로-2H-1,3,2-옥사자포스포린 P-옥시드와 코지산을 염기 존재하에 유기용매에서 반응시킨 후, 가수분해하고 극성 유기용매로 결정화함을 특징으로 한다.The present invention relates to a water-stable kojic acid derivative represented by the following structural formula (I) and a method for preparing the same, wherein 3-amino-1-propanol and phosphorus oxychloride are present in an organic solvent in the presence of an organic base in an equivalent ratio of 1: 1 to 1.3. 2-chlorotetrahydro-2H-1,3,2-oxazaphosphorine P-oxide and kojic acid produced by the reaction under the following reaction in an organic solvent in the presence of a base, followed by hydrolysis and crystallization with a polar organic solvent. It features.
(I)(I)
Description
본 발명은 하기 구조식(Ⅰ)로 표시되는 수안정형 코지산 유도체 및 그의 제조방법에 관한 것이다. 더욱 상세하게는 수안정성이 매우 우수하며, 3-아미노프로판인산과 코지산이 인산 디에스테르 형태로 연결되어 있기 때문에 생체내의 효소에 의해 분해되어 3-아미노프로판인산과 코지산의 생리활성을 나타낼 수 있는 코지산의 유도체 및 그의 제조방법에 관한 것이다.The present invention relates to a water-stable kojic acid derivative represented by the following structural formula (I) and a preparation method thereof. More specifically, the water stability is very excellent, and since 3-aminopropanoic acid and kojic acid are linked in the form of phosphate diester, they can be degraded by enzymes in vivo to exhibit the physiological activity of 3-aminopropaneic acid and kojic acid. A derivative of kojic acid and a method for producing the same.
(I)(I)
코지산은 구리 이온과 킬레이트를 형성하여 멜라닌 생성 기작시 주요한 역할을 하는 타이로시네이즈의 활성을 저해하는 물질 중의 하나로써, 이러한 코지산의 멜라닌 생성 억제 효과로 여러 화장품 제조에 코지산이 사용되고 있다. 그러나,코지산은 수상에서 안정도가 낮아 화장품에 응용시 장기간 보관하는 경우나 제조 공정에서 역가의 감소를 가져올 뿐만 아니라, 색상을 변화시키는 등 많은 문제점이 있다.Kojic acid is a substance that inhibits the activity of tyrosinase, which forms a chelate with copper ions, and plays a major role in melanin production, and kojic acid has been used in various cosmetic preparations to inhibit melanin production of kojic acid. However, Kojic acid has low stability in water phases, and there are many problems such as changing the color as well as reducing the titer in the case of long-term storage or manufacturing process when applied to cosmetics.
따라서, 코지산의 이러한 불안정성을 개선하기 위해서 이의 유도체화를 통해 활성 저해력 및 물성을 개선하고자 하였으나, 코지산은 4-위치의 카르복시기와 5-위치의 히드록시기가 활성부위이므로 이들을 보호(protecting)하면 활성을 저해한다고 알려져 있기 때문에, 대부분의 유도체들은 2-위치의 히드록시기를 치환하였다. 하지만, 이는 5-위치의 히드록시기의 보존으로 인해 착색 등의 안정도 향상은 크게 개선되지 못한 문제점이 있다.Therefore, in order to improve this instability of kojic acid, the inhibitory activity and physical properties were improved through derivatization thereof. However, since kojic acid is an active site of 4-position carboxyl group and 5-position hydroxy group, it is active by protecting them. Most derivatives have substituted a 2-positioned hydroxy group because it is known to inhibit. However, this has a problem in that stability improvement such as coloring is not greatly improved due to the preservation of the hydroxyl group at the 5-position.
이에, 본 발명자들은 코지산 유도체의 상기한 문제점을 해결할 목적으로, 수안정형 코지산의 유도체를 개발하고자 예의 연구하였다. 그 결과, 섬유아세포의 증식 및 콜라겐 합성에 관한 효과와 피부에 대한 안정성이 매우 우수하여 노화방지용 화장료 조성물의 유효성분으로 널리 사용되고 있는 3-아미노프로판인산을 코지산의 5-위치에 인산디에스테르 형태로 연결시키는 경우, 상기한 목적을 달성할 수 있음을 발견하고 본 발명을 완성하게 되었다.Accordingly, the present inventors earnestly studied to develop derivatives of water-stable kojic acid for the purpose of solving the above problems of kojic acid derivatives. As a result, 3-aminopropane phosphate, which is widely used as an active ingredient of anti-aging cosmetic composition because of its excellent effect on fibroblast proliferation and collagen synthesis and skin stability, is a phosphate diester form at the 5-position of kojic acid. In connection with the present invention, it was found that the above object can be achieved and the present invention has been completed.
따라서, 본 발명의 목적은 하기 구조식(Ⅰ)로 표시되는 수안정형 코지산 유도체를 제공하는 것이다.Accordingly, it is an object of the present invention to provide a water-stable kojic acid derivative represented by the following structural formula (I).
(Ⅰ)(Ⅰ)
나아가, 본 발명의 다른 목적은, 상기한 코지산의 제조방법을 제공하는 것이다.Further, another object of the present invention is to provide a method for producing kojic acid described above.
상기한 목적은, 2-클로로테트라히드로-2H-1,3,2-옥사자포스포린 P-옥시드와 코지산을 반응시킴으로써 달성될 수 있으며, 보다 구체적으로 본 발명에 따른 코지산 유도체의 제조방법은, 우선, 3-아미노-1-프로판올과 옥시염화인을 1 : 1~1.3의 당량비로 유기염기 존재하에 유기용매하에서 0∼5℃의 온도로 1∼2시간 동안 반응시켜서 2-클로로테트라히드로-2H-1,3,2-옥사자포스포린 P-옥시드를 제조한 후, 이를 염기 존재하에 코지산과 반응시키고, 가수분해한 후, 극성 유기용매로 결정화시킴을 특징으로 한다.The above object can be achieved by reacting 2-chlorotetrahydro-2H-1,3,2-oxazaphosphorine P-oxide with kojic acid, and more specifically, a method for preparing kojic acid derivative according to the present invention. First, 2-amino-1-propanol and phosphorus oxychloride are reacted for 1 to 2 hours at an temperature of 0 to 5 ° C. in an organic solvent in the presence of an organic base in an equivalent ratio of 1: 1 to 1.3, and then 2-chlorotetrahydro It is characterized in that -2H-1,3,2-oxazaphosphorin P-oxide is prepared, which is then reacted with kojic acid in the presence of a base, hydrolyzed and crystallized with a polar organic solvent.
이하 본 발명을 보다 구체적으로 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명에 따른 코지산 유도체의 제조방법은,Method for producing a kojic acid derivative according to the present invention,
(A) 3-아미노-1-프로판올과 옥시염화인을 1 : 1~1.3의 당량비로 유기염기 존재하에 유기용매하에서 0∼5℃의 온도로 1∼2시간 동안 반응시켜 2-클로로테트라히드로-2H-1,3,2-옥사자포스포린 P-옥시드를 생성시키는 단계 ;(A) 3-amino-1-propanol and phosphorus oxychloride were reacted for 1 to 2 hours at an temperature of 0 to 5 DEG C in an organic solvent in the presence of an organic base in an equivalent ratio of 1: 1 to 1.3. Producing 2H-1,3,2-oxazaphosphorine P-oxide;
(B) 상기 (A)단계에서 생성된 2-클로로테트라히드로-2H-1,3,2-옥사자포스포린 P-옥시드와 코지산을 염기 존재하에 유기용매에서 반응시키는 단계;(B) reacting 2-chlorotetrahydro-2H-1,3,2-oxazaphosphorine P-oxide and kojic acid produced in step (A) in an organic solvent in the presence of a base;
(C) 반응액을 여과하여 얻은 여액을 감압, 농축한 후 얻어진 잔사에 산용액을 부가하여 5∼100℃의 온도에서 약 3 ~ 10시간 동안 반응하여 가수분해시키는 단계; 및(C) depressurizing and concentrating the filtrate obtained by filtering the reaction solution, and then adding an acid solution to the obtained residue to react and hydrolyze at a temperature of 5 to 100 ° C. for about 3 to 10 hours; And
(D) 극성 유기용매로 결정화하는 단계;(D) crystallizing with polar organic solvent;
를 포함하는 것을 특징으로 한다.Characterized in that it comprises a.
본 발명에 따른 제조방법은 다음의 반응식 1로 도식화될 수 있다 :The preparation method according to the invention can be represented by the following scheme 1:
본 발명에 따른 코지산 유도체의 제조방법을 상기한 반응식 1에서 알 수 있는 바와 같이, 구체적으로 설명하면 다음과 같다.As can be seen in Scheme 1, a method for preparing a kojic acid derivative according to the present invention is described in detail as follows.
(A) 유기염기 존재하에 유기용매에서 3-아미노-1-프로판올과 옥시염화인을 0∼5℃의 온도에서 1∼2시간동안 교반하여 상기 구조식 (II)로 표시되는 2-클로로테트라히드로-2H-1,3,2-옥사자포스포린P-옥시드(2-Chlorotetrahydro-2H-1,3,2-oxaza phosphorin P-oxide)를 생성시키는 단계;(A) 2-chlorotetrahydro- represented by the above formula (II) by stirring 3-amino-1-propanol and phosphorus oxychloride in an organic solvent for 1 to 2 hours at a temperature of 0 to 5 ° C. in the presence of an organic base. Producing 2H-1,3,2-oxazaphosphorin P-oxide; 2-Chlorotetrahydro-2H-1,3,2-oxaza phosphorin P-oxide;
상기한 단계에서 3-아미노-1-프로판올과 옥시염화인은 1:1∼1.3의 당량비로 반응시키는 것이 바람직하다. 당량비가 1:1 미만이면 목적하는 생성물을 얻을 수 없고, 1: 1.3 이상이면 목적하는 생성물 이외에 과량의 부산물이 생성된다. 따라서, 상기한 방법으로 2-클로로테트라히드로-2H-1,3,2-옥사자포스포린 P-옥시드를 제조하는 경우, 3-아미노-1-프로판올과 옥시염화인이 1:1로 결합한 중간체가 95이상 생성되고, 3-아미노-1-프로판올과 옥시염화인이 2:1로 결합한 부산물이 1∼2이하로 생성된다. 그러나, 상기한 부산물은 크로마토그래피를 이용하여 분리하거나, 톨루엔에 대한 용해도 차이를 이용하여 용이하게 제거할 수 있다. 특히, 옥시염화인 분자내의 3개의 염소원자 중 두개의 염소원자가 3-아미노-1-프로판올의 두 관능기, 즉 수산기와 아민기에 의해 치환되어 고리화된 2-클로로테트라히드로-2H-1,3,2-옥사자포스포린 P-옥시드가 생성되며, 나머지 하나의 염소원자는 5℃이하의 저온에서는 반응성이 감소되어 치환되지 않고 그대로 남아 있게 된다. 이는 2-클로로테트라히드로-2H-1,3,2-옥사자포스포린 P-옥시드의 염소원자가 저온의 무수 비활성 용매 중에서 안정하여 3-아미노-1-프로판올과 쉽게 치환되지 않기 때문이다. 따라서, 본 발명의 제조방법은 3-아미노-1-프로판올과 옥시염화인을 1:1.0∼1.3의 당량비로하여 0∼5℃의 온도에서 1∼2시간 동안 반응시키므로, 3-아미노-1-프로판올과 옥시염화인이 2:1 이상으로 반응한 부산물의 생성을 방지할 수 있으며, 특히 옥시염화인 중 하나의 염소원자를 보호하기 위해 에스테르기나, 아미드기를 도입하는 공정이 필요하지 않으므로, 반응공정을 줄일 수 있는 장점이 있다.In the above step, 3-amino-1-propanol and phosphorus oxychloride are preferably reacted in an equivalent ratio of 1: 1 to 1.3. If the equivalent ratio is less than 1: 1, the desired product cannot be obtained, and if it is 1: 1.3 or more, an excess of by-products are produced in addition to the desired product. Therefore, when 2-chlorotetrahydro-2H-1,3,2-oxazaphosphorine P-oxide is prepared by the above-described method, an intermediate in which 3-amino-1-propanol and phosphorus oxychloride are 1: 1 bound Is produced in more than 95, and by-products of 2-amino-1-propanol and phosphorus oxychloride 2: 1 are produced in 1 or less. However, the by-products can be separated using chromatography, or easily removed by using a difference in solubility in toluene. In particular, two chlorine atoms of the three chlorine atoms in the phosphorus oxychloride molecule are substituted with two functional groups of 3-amino-1-propanol, ie, hydroxyl and amine groups, and cyclized 2-chlorotetrahydro-2H-1,3, A 2-oxaphosphorine P-oxide is produced, and the other chlorine atom is reduced in reactivity at 5 ° C. or lower and remains unsubstituted. This is because the chlorine atom of 2-chlorotetrahydro-2H-1,3,2-oxazaphosphorine P-oxide is stable in a low temperature anhydrous inert solvent and is not easily substituted with 3-amino-1-propanol. Therefore, in the preparation method of the present invention, 3-amino-1-propanol and phosphorus oxychloride are reacted at a temperature of 0 to 5 ° C. for 1 to 2 hours at an equivalent ratio of 1: 1.0 to 1.3. Propanol and phosphorus oxychloride can prevent the formation of by-products reacted at 2: 1 or more, and in particular, it is not necessary to introduce ester groups or amide groups in order to protect chlorine atoms of phosphorus oxychloride. There is an advantage to reduce.
본 발명의 제조방법 중 (A)단계에서 유기염기로는 피리딘, 트리에틸아민 등을 사용할 수 있으나, 트리에틸아민을 사용하는 것이 바람직하다.As the organic base in step (A) of the preparation method of the present invention, pyridine, triethylamine, and the like may be used, but triethylamine is preferably used.
본 발명의 제조방법 중 (A) 단계에서 유기용매로는 디클로로메탄, 테트라히드로퓨란, 초산에틸, 아세토니트릴, 클로로포름, 에틸에테르 등과 같은 비활성 용매를 사용할 수 있으나, 클로로포름을 사용하는 것이 바람직하다.In the method (A) of the present invention, the organic solvent may be an inert solvent such as dichloromethane, tetrahydrofuran, ethyl acetate, acetonitrile, chloroform, ethyl ether, etc., but it is preferable to use chloroform.
한편, 반응온도는 5℃이상에서는 2당량 이상의 3-아미노-1-프로판올이 옥시염화인에 치환되어 부산물의 생성이 증가되고, 0℃미만의 온도에서는 반응물의 용해도가 감소되어 반응의 진행이 어려우며, 미반응물의 함량이 증가되어 반응 수율이 낮아지므로 0∼5℃ 범위의 온도가 바람직하다.On the other hand, the reaction temperature is more than 2 equivalents of 3-amino-1-propanol is substituted with phosphorus oxychloride to increase the production of by-products, and the temperature of less than 0 ℃ to reduce the solubility of the reactants difficult to proceed the reaction. In this case, a temperature in the range of 0 to 5 ° C. is preferable because the content of unreacted material is increased to lower the reaction yield.
(B) 2-클로로테트라히드로-2H-1,3,2-옥사자포스포린 P-옥시드와 코지산을 염기존재하에 유기용매에서 반응시키는 단계;(B) reacting 2-chlorotetrahydro-2H-1,3,2-oxazaphosphorine P-oxide with kojic acid in the presence of a base in an organic solvent;
본 발명의 제조방법 중 (B)단계에서 염기로는 상기 공정(A)에서 설명한 바와 같이 피리딘, 트리에틸아민 등의 유기염기를 사용할 수 있으며, 나트륨, 소디움 히드록사이드, 포타슘 히드록사이드 등의 염기도 사용할 수 있으나, 포타슘 히드록사이드를 사용하는 것이 바람직하다.As the base in step (B) of the production method of the present invention, organic bases such as pyridine and triethylamine may be used as described in step (A), and sodium, sodium hydroxide, potassium hydroxide, and the like may be used. Bases may also be used, but preference is given to using potassium hydroxide.
본 발명의 제조방법 중 (B)단계에서 유기용매로는 디클로로메탄, 테트라히드로퓨란, 초산에틸, 아세토니트릴, 클로로포름, 에틸에테르 등과 같은 비활성 용매 및 메탄올 에탄올, 프로판올등의 극성 용매를 사용할 수 있으나, 메탄올을 사용하는 것이 바람직하다.In the (B) step of the production method of the present invention as an organic solvent may be used an inert solvent such as dichloromethane, tetrahydrofuran, ethyl acetate, acetonitrile, chloroform, ethyl ether, and a polar solvent such as methanol ethanol, propanol, Preference is given to using methanol.
(C) 반응액을 여과하여 얻은 여액을 감압 농축한 후, 얻어진 잔사에 산용액을 부가하여 약 5∼100℃의 온도에서 약 3 ~ 10시간 동안 반응시켜 가수분해시키는 단계 ;(C) concentrating the filtrate obtained by filtration of the reaction solution under reduced pressure, and then adding an acid solution to the obtained residue to react for about 3 to 10 hours at a temperature of about 5 to 100 ° C. for hydrolysis;
본 발명에 따른 제조방법에서 반응액을 여과하여 얻은 여액을 감압 농축하여 얻은 잔사의 가수분해는 일반적인 가수분해 조건인 강 양이온 교환수지(Amberlyst 15), 염산 또는 황산 등의 산촉매를 사용하여 가수분해할 수 있다. 즉, 얻어진 위의 (B)단계 화합물에 산용액을 부가한 후 5∼100℃온도로 승온하여 교반하는 경우 P-N결합이 가수분해될 수 있다. 따라서, 반응액을 여과하여 얻은 여액을 농축한 후 얻은 잔사에 산용액을 부가하여 약 5∼100℃온도, 바람직하게는 40℃ 온도에서 약 5시간동안 반응시켜서 가수분해시키는 것이 바람직하다. 산용액의 pH는 1~5, 바람직하게는 2~4이다.Hydrolysis of the residue obtained by concentrating the filtrate obtained by filtration of the reaction solution under reduced pressure in the production method according to the present invention can be hydrolyzed using an acid catalyst such as strong cation exchange resin (Amberlyst 15), hydrochloric acid or sulfuric acid, which are general hydrolysis conditions. Can be. That is, after the acid solution is added to the obtained compound (B), the P-N bond may be hydrolyzed when the mixture is heated and stirred at a temperature of 5 to 100 ° C. Therefore, it is preferable to add an acid solution to the residue obtained by concentrating the filtrate obtained by filtration of the reaction solution, and to react it for about 5 hours at a temperature of about 5 to 100 ° C., preferably 40 ° C. for hydrolysis. The pH of the acid solution is 1-5, preferably 2-4.
(D) 극성 유기용매를 서서히 적가하여 코지산의 유도체인 코지산, 3-아미노프로판올 인산 디에스테르를 결정화하는 단계 ;(D) gradually dropping the polar organic solvent to crystallize koji acid, 3-aminopropanol phosphate diester, which is a derivative of koji acid;
본 발명에서 사용되는 석출 용매인 극성 유기용매는 특별히 한정되지는 않지만, 예를 들면, 메탄올, 에탄올, 이소프로판올, 아세톤, 테트라히드로퓨란, 아세토니트릴 또는 디옥산을 사용할 수 있다.Although the polar organic solvent which is a precipitation solvent used by this invention is not specifically limited, For example, methanol, ethanol, isopropanol, acetone, tetrahydrofuran, acetonitrile, or dioxane can be used.
상기한 제조방법에 의해 제공되는 코지산의 유도체는 이를 중화하여 염의 형태로도 사용할 수 있는데, 구체적인 예로는 나트륨, 칼륨 등의 알칼리금속류염; 칼슘, 마그네슘 등의 알칼리토금속류염; 트리에탄올아민 등의 아민 또는 암모니아에 의한 염의 형태로 사용될 수 있다.Derivatives of kojic acid provided by the above-mentioned manufacturing method may be used in the form of salts by neutralizing them, and specific examples thereof include alkali metal salts such as sodium and potassium; Alkaline earth metal salts such as calcium and magnesium; Amines such as triethanolamine or salts with ammonia.
이하 실시예를 통하여 본 발명에 따른 코지산 유도체의 제조방법을 보다 구체적으로 설명한다. 그러나, 본 발명이 이들 실시예에 한정되는 것은 아니다.Hereinafter, the preparation method of kojic acid derivative according to the present invention will be described in more detail with reference to the following examples. However, the present invention is not limited to these examples.
[제조예] 2-클로로테트라히드로-2H-1,3,2-옥사자포스포린P-옥시드(2-Chlorotetrahydro-2H-1,3,2-oxaza phosphorin P-oxide)[Production Example] 2-Chlorotetrahydro-2H-1,3,2-oxazaphosphorine P-oxide (2-Chlorotetrahydro-2H-1,3,2-oxaza phosphorin P-oxide)
옥시염화인 34.1㎖(0.36mol)을 디클로로메탄 400㎖에 녹인 다음 얼음물 중탕에서 용액을 0∼5℃로 냉각시켰다. 다른 용기에 3-아미노-1-프로판올 30㎖(0.39mol)와 트리에틸아민 102㎖(0.73mol)용액을 디클로로메탄 200㎖로 희석한 후, 앞에서 제조한 반응용액을 2시간 동안 적가하였다. 적가가 끝난 후 생성된 트리에틸암모늄클로라이드를 제거하였다. 여액은 100㎖ 정제수를 사용하여 세척하고, 무수황산나트륨으로 건조시킨 다음, 여과하고, 감압하여 농축하였다. 농축한 후, 얻어진 잔사에 톨루엔을 가하여 결정을 얻었다. 얻어진 결정은 진공건조하여 반응생성물인 2-클로로테트라히드로-2H-1,3,2-옥사자포스포린 P-옥시드를 53g의 백색고체로서 얻었다.34.1 mL (0.36 mol) of phosphorus oxychloride was dissolved in 400 mL of dichloromethane, and the solution was cooled to 0-5 ° C. in an ice water bath. In another vessel, 30 mL (0.39 mol) of 3-amino-1-propanol and 102 mL (0.73 mol) of triethylamine were diluted with 200 mL of dichloromethane, and the reaction solution prepared above was added dropwise for 2 hours. After the addition, the triethylammonium chloride produced was removed. The filtrate was washed with 100 ml purified water, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. After concentration, toluene was added to the obtained residue to obtain a crystal. The obtained crystals were dried in vacuo to give 53 g of white solid as a reaction product, 2-chlorotetrahydro-2H-1,3,2-oxazaphosphorine P-oxide.
m.p. : 79∼82℃m.p. : 79 ~ 82 ℃
IR(CHCl3, ㎝-1) : 3254, 1477, 1274, 1092, 1036, 996IR (CHCl 3 , cm −1 ): 3254, 1477, 1274, 1092, 1036, 996
1H-NMR(CDCl3) : δ(ppm) = 1.7(m, 1H), 1.1(m, 1H), 3.3(m, 2H), 4.4(m,2H), 4.9(br, 1H) 1 H-NMR (CDCl 3 ): δ (ppm) = 1.7 (m, 1H), 1.1 (m, 1H), 3.3 (m, 2H), 4.4 (m, 2H), 4.9 (br, 1H)
[실시예 1] 코지산, 3-아미노프로판올 인산 디에스테르Example 1 Kojic acid, 3-aminopropanol phosphate diester
코지산 10g을 메탄올 80㎖에 녹인 다음, 포타슘 히드록사이드 4.3g을 메탄올 20㎖에 녹인 액을 서서히 적가하여 실온에서 30분 교반하였다. 동온도에서 제조예에서 제조한 2-클로로테트라히드로-2H-1,3,2-옥사자포스포린 P-옥시드 11.2g(1.1 eq)을 서서히 적가하였다. 적가가 끝난 후 하룻밤동안 상온에서 교반한 후, 반응액을 여과하고 얻은 여액을 감압 농축한 후 0~5℃ 에서 하루밤 방치하였다. 생성된 고체를 여과하고 진공건조하여 목적물 [2-(히드록시메틸)-4-옥소-4H-피란-5-일옥시]-1,3,2-옥사자포스포린 P-옥시드를 백색고체로 얻었다.10 g of kojic acid was dissolved in 80 ml of methanol, and a solution of 4.3 g of potassium hydroxide in 20 ml of methanol was slowly added dropwise and stirred at room temperature for 30 minutes. At the same temperature, 11.2 g (1.1 eq) of 2-chlorotetrahydro-2H-1,3,2-oxazaphosphorine P-oxide prepared in Preparation Example was slowly added dropwise. After the addition was completed, the mixture was stirred at room temperature overnight, the reaction solution was filtered and the filtrate was concentrated under reduced pressure, and then left at 0-5 ° C. overnight. The resulting solid was filtered and dried in vacuo to give the desired product [2- (hydroxymethyl) -4-oxo-4H-pyran-5-yloxy] -1,3,2-oxazaphosphorine P-oxide as a white solid. Got it.
이를 pH 4의 수용액 30㎖에 녹이고, 40℃ 항온조에서 5시간 동안 교반하였다. 교반이 끝난 반응액에 이소프로판올 150㎖를 가하여 결정을 얻고, 얻어진 결정을 진공건조하여 생성물인 코지산, 3-아미노프로판올 인산 디에스테르를 16g의 미황색 고체로서 얻었다.It was dissolved in 30 ml of an aqueous solution of pH 4, and stirred for 5 hours in a 40 ℃ thermostat. 150 ml of isopropanol was added to the stirred reaction solution to obtain crystals, and the obtained crystals were dried in vacuo to yield 16 g of kojic acid and 3-aminopropanol phosphate diester as products as a pale yellow solid.
m.p. : 118∼128℃(분해)m.p. : 118 to 128 ° C (decomposition)
IR(KBr, ㎝-1) : 3446, 3322, 2904, 1658, 1616, 1250, 1090, 863IR (KBr, cm −1 ): 3446, 3322, 2904, 1658, 1616, 1250, 1090, 863
1H-NMR(D2O) : δ(ppm) = 2.05(m, 2H), 3.15(t, 2H), 4.12(m, 2H), 4.54(m, 2H), 6.64(s, 1H), 8.27(s,1H) 1 H-NMR (D 2 O): δ (ppm) = 2.05 (m, 2H), 3.15 (t, 2H), 4.12 (m, 2H), 4.54 (m, 2H), 6.64 (s, 1H), 8.27 (s, 1H)
[실시예 2] 코지산, 3-아미노프로판올 인산 디에스테르 나트륨염Example 2 Koji acid, 3-aminopropanol phosphate diester sodium salt
실시예 1에서 얻은 코지산, 3-아미노프로판올 인산 디에스테르 1g을 정제수30㎖에 녹인 후, 여기에 5탄산나트륨 수용액을 부가하여 pH 7로 만들었다. 상기 용액을 동결 건조하여 코지산, 3-아미노프로판올 인산 디에스테르 나트륨염을 백색고체로서 얻었다.After dissolving 1 g of kojic acid and 3-aminopropanol phosphate diester obtained in Example 1 in 30 ml of purified water, an aqueous sodium carbonate solution was added thereto to pH 7. The solution was lyophilized to give kojic acid and 3-aminopropanol phosphate diester sodium salt as a white solid.
[실시예 3] 코지산, 3-아미노프로판올 인산 디에스테르 칼륨염EXAMPLE 3 Koji acid and 3-aminopropanol phosphate diester potassium salt
실시예 1에서 얻은 코지산, 3-아미노프로판올 인산 디에스테르 1g을 정제수 30㎖에 녹인 후, 여기에 5탄산칼륨 수용액을 부가하여 pH 7로 만들었다. 상기 용액을 동결 건조하여 코지산, 3-아미노프로판올 인산 디에스테르 칼륨염을 백색고체로서 얻었다.After dissolving 1 g of kojic acid and 3-aminopropanol phosphate diester obtained in Example 1 in 30 ml of purified water, an aqueous potassium carbonate solution was added thereto to make pH 7. The solution was lyophilized to obtain kojic acid and 3-aminopropanol phosphate diester potassium salt as a white solid.
[실시예 4] 코지산, 3-아미노프로판올 인산 디에스테르 칼슘염EXAMPLE 4 Koji acid and 3-aminopropanol phosphate diester calcium salt
실시예 1에서 얻은 코지산, 3-아미노프로판올 인산 디에스테르 1g을 정제수 30㎖에 녹인 후, 여기에 수산화칼륨을 부가하여 pH 7로 만들었다. 상기 용액을 동결 건조하여 코지산, 3-아미노프로판올 인산 디에스테르 칼슘염을 백색고체로서 얻었다.1 g of kojic acid and 3-aminopropanol phosphate diester obtained in Example 1 was dissolved in 30 ml of purified water, and potassium hydroxide was added thereto to pH 7. The solution was lyophilized to obtain kojic acid and 3-aminopropanol phosphate diester calcium salt as a white solid.
[실시예 5] 코지산, 3-아미노프로판올 인산 디에스테르 마그네슘염EXAMPLE 5 Koji acid and 3-aminopropanol phosphate diester magnesium salt
실시예 1에서 얻은 코지산, 3-아미노프로판올 인산 디에스테르 1g을 정제수 30㎖에 녹인 후, 여기에 산화마그네슘을 부가하여 pH 7로 만들었다. 상기 용액을 동결 건조하여 코지산, 3-아미노프로판올 인산 디에스테르 마그네슘염을 백색고체로서 얻었다.1 g of kojic acid and 3-aminopropanol phosphate diester obtained in Example 1 were dissolved in 30 ml of purified water, and magnesium oxide was added thereto to pH 7. The solution was lyophilized to obtain kojic acid and 3-aminopropanol phosphate diester magnesium salt as a white solid.
[실시예 6] 코지산, 3-아미노프로판올 인산 디에스테르 트리에탄올아민염Example 6 Kojic acid, 3-Aminopropanol phosphate diester triethanolamine salt
실시예 1에서 얻은 코지산, 3-아미노프로판올 인산 디에스테르 1g을 정제수30㎖에 녹인 후, 여기에 5트리에탄올아민 수용액을 부가하여 pH 7로 만들었다. 상기 용액을 동결 건조하여 코지산, 3-아미노프로판올 인산 디에스테르 트리에탄올아민염을 백색고체로서 얻었다.After dissolving 1 g of kojic acid and 3-aminopropanol phosphate diester obtained in Example 1 in 30 ml of purified water, 5 triethanolamine aqueous solution was added thereto to pH 7. The solution was lyophilized to obtain kojic acid and 3-aminopropanol phosphate diester triethanolamine salt as a white solid.
[시험예 1][Test Example 1]
실시예 1의 화합물인 코지산, 3-아미노프로판올 인산 디에스테르와 코지산 각각 2g을 pH 2~pH 8의 각각의 수용액 100㎖에 녹인 다음, 50℃ 항온조에서 3주 동안 보관한 후 착색 유무 등의 경시변화를 하기 평가기준에 따라 관찰하고, 그 결과를 표 1에 나타내었다.2 g of each of kojic acid, 3-aminopropanol phosphate diester and kojic acid, which are the compounds of Example 1, were dissolved in 100 ml of each aqueous solution of pH 2 to pH 8, and then stored in a 50 ° C. thermostat for 3 weeks, and then colored. The change over time was observed according to the following evaluation criteria, and the results are shown in Table 1.
<평가기준><Evaluation Criteria>
- : 무색 또는 미황색 + : 착색 소-: Colorless or light yellow +: coloring pigment
++ : 착색 중 +++ : 착색 대++: during coloring +++: coloring
상기 표 1에서 알 수 있는 바와 같이, 본 발명의 화합물은 수상에서 매우 안정하고 고순도이기 때문에 변색이 일어나지 않고, 침전이 생성되지 않는다.As can be seen from Table 1, the compound of the present invention is very stable and high purity in the water phase, so no discoloration occurs, no precipitation is produced.
[시험예 2][Test Example 2]
실시예 1의 화합물인 코지산, 3-아미노프로판올 인산 디에스테르와 코지산을 각각 50μM의 농도로 하이드리온(hydrion) pH 7 완충 용액에 녹인 다음, 50℃ 항온조에서 보관한 후 일정 시간마다, 254㎚에서 UV 흡수도를 측정하였다. 시료 용액중의 시료 잔존율()을 표 2에 나타내었다.Example 1 Compounds of kojic acid, 3-aminopropanol phosphate diester and kojic acid were dissolved in a hydrion pH 7 buffer solution at a concentration of 50 μM, respectively, and then stored in a 50 ° C. thermostat, and then at a constant time, 254 UV absorbance was measured at nm. Table 2 shows the sample residual ratio () in the sample solution.
일반적으로 희석농도에서 시료의 안정성은 크게 저하된다. 그러나, 표 2에서 알 수 있는 바와 같이, 실시예 1의 화합물은 중성의 수용액에서 안정한 상태로 존재하나 코지산 수용액은 1시간 이내에 거의 분해된다.In general, the stability of the sample at dilution concentration is greatly reduced. However, as can be seen from Table 2, the compound of Example 1 is present in a stable state in a neutral aqueous solution, but the aqueous kojic acid solution is almost decomposed within 1 hour.
본 발명의 방법에 의해 제공된 코지산의 유도체인 코지산, 3-아미노프로판올 인산 디에스테르 또는 그의 염은 수상에서 안정하고 고순도이기 때문에 수상제품에 응용이 용이하고, 또한, 생체내의 효소(포스파타아제 등)작용에 의해 멜라닌 생성 억제능을 가진 코지산과, 인체섬유아세포를 증식시키며, 교원질섬유(콜라젠)의 합성을 촉진하고, 더구나 인체 피부 안정성이 우수한 3-아미노프로판인산으로 분해될 수 있기 때문에, 특히 미백 및 노화방지용 화장료 조성물의 원료로서 유용하게 사용될 수 있을 것이다.Kojic acid, 3-aminopropanol phosphate diester, or a salt thereof, which is a derivative of kojic acid provided by the method of the present invention, is stable in water phase and has a high purity, and thus is easy to be applied to a water product, and also an enzyme in vivo (phosphatase). Etc.), it is possible to proliferate kojic acid having melanin production and human fibroblasts, promote the synthesis of collagen fibers (collagen), and further break down into 3-aminopropane phosphate having excellent human skin stability. It may be usefully used as a raw material for the whitening and anti-aging cosmetic composition.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990034754A KR100320037B1 (en) | 1999-08-21 | 1999-08-21 | Water-stable-form kojic acid derivatives and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990034754A KR100320037B1 (en) | 1999-08-21 | 1999-08-21 | Water-stable-form kojic acid derivatives and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010018695A KR20010018695A (en) | 2001-03-15 |
KR100320037B1 true KR100320037B1 (en) | 2002-01-10 |
Family
ID=19608147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019990034754A KR100320037B1 (en) | 1999-08-21 | 1999-08-21 | Water-stable-form kojic acid derivatives and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100320037B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100376088B1 (en) * | 2001-03-09 | 2003-03-28 | 주식회사 태평양 | Whitening cosmetics composition comprising a 3-Aminopropyl Kojylphosphate |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100493726B1 (en) * | 2002-07-16 | 2005-06-03 | 주식회사 펩트론 | Kojic acid derivatives, preparation method and use thereof |
-
1999
- 1999-08-21 KR KR1019990034754A patent/KR100320037B1/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100376088B1 (en) * | 2001-03-09 | 2003-03-28 | 주식회사 태평양 | Whitening cosmetics composition comprising a 3-Aminopropyl Kojylphosphate |
Also Published As
Publication number | Publication date |
---|---|
KR20010018695A (en) | 2001-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SU850001A3 (en) | Method of preparing proline derivatives | |
KR100320037B1 (en) | Water-stable-form kojic acid derivatives and preparation method thereof | |
KR930011283B1 (en) | Process for the synthesis of 3'-azido-3'-dexythymidine and the like | |
US6197998B1 (en) | Process for producing N-glycyltyrosine and its crystal structure | |
KR100230653B1 (en) | Water stable L-ascorbic acid derivatives and a method for preparation thereof | |
US5250689A (en) | Process for the production of 2-(methylthio)-disodium barbiturate | |
DE2151530C3 (en) | Process for the preparation of 7-aminocephalosporanic acids | |
SU626094A1 (en) | 5-substituted derivatives of 5h-dibenz(b,f) azepine as intermidiate products of synthesis of compounds exhibiting psychotropic effect and method of producing same | |
KR100411205B1 (en) | Menthol derivatives and process for preparing the same | |
US4145558A (en) | Ester derivatives of ether polycarboxylic acids | |
CA2280381C (en) | Improved process for the production of an n-acyl derivative of o,s-dialkyl phosphoroamidothioate | |
US4668798A (en) | Process for preparing pyrrolidine derivatives | |
KR100187900B1 (en) | A method of preparation of 3-aminopropane-phosphoric acid | |
US5659035A (en) | Substituted phosphonic acids | |
KR850000612B1 (en) | Process for preparing alpha-amino benzyl penicillin esters | |
KR860000589B1 (en) | Process for preparing quinoline carboxylic acid derivatives | |
SU1671660A1 (en) | Method for preparation of 2-selenooxo-5- arylideneimidazolidine-4-ones | |
SU1605923A3 (en) | Mp4ъ-(9-acrydinylamine)-3ъ-methoxymethanesulfonanilide or its lactate | |
KR100502390B1 (en) | Process for preparing cephalosporinic acid | |
KR950001632B1 (en) | N-(3',4'-dimethoxycinnamoyl)anthranilic acid | |
KR820000881B1 (en) | Process for preparing thizolidine derivatives | |
JP3127505B2 (en) | Method for producing pyrazolopyridine derivative | |
US4642375A (en) | Process for preparing derivatives of the monoamide of terephthalic acid | |
KR830001686B1 (en) | Method for producing amino arylthiophosphates and aminoaryl phosphates | |
KR920004932B1 (en) | Method of producing for pyridine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121127 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20131121 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20141120 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20151130 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20161010 Year of fee payment: 16 |
|
FPAY | Annual fee payment |
Payment date: 20170928 Year of fee payment: 17 |
|
FPAY | Annual fee payment |
Payment date: 20181002 Year of fee payment: 18 |